{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:06:28Z","timestamp":1762603588582},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1989,8,1]],"date-time":"1989-08-01T00:00:00Z","timestamp":617932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":9624,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[1989,8]]},"DOI":"10.1038\/ki.1989.189","type":"journal-article","created":{"date-parts":[[2007,5,29]],"date-time":"2007-05-29T11:32:06Z","timestamp":1180438326000},"page":"266-271","source":"Crossref","is-referenced-by-count":34,"title":["Treatment of nephrotic hyperlipoproteinemia with gemfibrozil"],"prefix":"10.1016","volume":"36","author":[{"given":"Gerald C.","family":"Groggel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred K.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ellis-Benigni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.1989.189_bb0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1038\/ki.1989.189_bb0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1038\/ki.1989.189_bb0020","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.1038\/ki.1989.189_bb0025","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.1989.189_bb0030","first-page":"283","article-title":"Plasma-lipoids in renal disease","volume":"6","author":"Daniels","year":"1925","journal-title":"Br J Exp Pathol"},{"key":"10.1038\/ki.1989.189_bb0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5694\/j.1326-5377.1974.tb93641.x","article-title":"Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man","volume":"2","author":"Alexander","year":"1974","journal-title":"Med J Aust"},{"key":"10.1038\/ki.1989.189_bb0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000182024","article-title":"The nephrotic syndrome and ischaemic heart disease","volume":"27","author":"Mallick","year":"1981","journal-title":"Nephron"},{"key":"10.1038\/ki.1989.189_bb0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(69)90110-X","article-title":"Ischaemic heart-disease as a complication of nephrotic syndrome","volume":"2","author":"Berlyne","year":"1969","journal-title":"Lancet"},{"key":"10.1038\/ki.1989.189_bb0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0002-9343(77)90231-5","article-title":"Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated","volume":"63","author":"Curry","year":"1977","journal-title":"Am J Med"},{"key":"10.1038\/ki.1989.189_bb0055","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(79)92067-1","article-title":"Does the nephrotic syndrome increase the risk of cardiovascular disease","volume":"2","author":"Wass","year":"1979","journal-title":"Lancet"},{"key":"10.1038\/ki.1989.189_bb0060","series-title":"Contemporary Issues In Nephrology","first-page":"281","article-title":"Management of nephrotic syndrome","author":"Coggins","year":"1982"},{"key":"10.1038\/ki.1989.189_bb0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0272-6386(87)80170-1","article-title":"The nephrotic syndrome and its complications","volume":"10","author":"Cameron","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.1989.189_bb0070","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0140-6736(72)91905-8","article-title":"Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia","volume":"2","author":"Bridgman","year":"1972","journal-title":"Lancet"},{"key":"10.1038\/ki.1989.189_bb0075","first-page":"370","article-title":"Effect of clofibrate on serum and hepatic lipids in nephrotic rats","volume":"19","author":"Hoak","year":"1968","journal-title":"Lab Invest"},{"key":"10.1038\/ki.1989.189_bb0080","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000390006","article-title":"Management of the idiopathic nephrotic syndrome","volume":"23","author":"Glassock","year":"1980","journal-title":"Contr Nephrol"},{"key":"10.1038\/ki.1989.189_bb0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000181842","article-title":"Chronic clofibrate therapy in maintenance hemodialysis patients","volume":"25","author":"Sherrard","year":"1980","journal-title":"Nephron"},{"key":"10.1038\/ki.1989.189_bb0090","first-page":"113","article-title":"Gemfibrozil: Treatment of dyslipidemias in renal failure with uremia or in the nephrotic syndrome","volume":"2","author":"Manninen","year":"1982","journal-title":"Res Clin For"},{"key":"10.1038\/ki.1989.189_bb0095","series-title":"The Lipid Research Clinics Population Studies Data Book","year":"1980"},{"key":"10.1038\/ki.1989.189_bb0100","series-title":"The Lipid Research Clinics Program","year":"1974"},{"key":"10.1038\/ki.1989.189_bb0105","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/clinchem\/33.11.2065","article-title":"New assays of apolipoprotein A-l and B by rate nephelometry evaluated","volume":"33","author":"Maciejko","year":"1987","journal-title":"Clin Chem"},{"key":"10.1038\/ki.1989.189_bb0110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1038\/ki.1989.189_bb0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0021-9150(87)90278-4","article-title":"Change in composition of high density lipoprotein during gemfibrozil therapy","volume":"67","author":"Sorisky","year":"1987","journal-title":"Atherosclerosis"},{"issue":"Suppl 5B","key":"10.1038\/ki.1989.189_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(87)90866-7","article-title":"Fibric GL: Fibric acids: Effects on lipids and lipoprotein metabolism","volume":"83","author":"Grundy","year":"1987","journal-title":"Am J Med"},{"key":"10.1038\/ki.1989.189_bb0125","first-page":"38","article-title":"Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"148","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.1989.189_bb0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0021-9150(85)90181-9","article-title":"Lipoprotein distribution and composition in the human nephrotic syndrome","volume":"54","author":"Muls","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1038\/ki.1989.189_bb0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/01.ATV.5.5.466","article-title":"Demographic, behavioral, biochemical, and dietary correlates of plasma triglycerides","volume":"5","author":"Cowan","year":"1985","journal-title":"Arteriosclerosis"},{"key":"10.1038\/ki.1989.189_bb0140","first-page":"82","article-title":"Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic syndrome","volume":"9","author":"Schapel","year":"1974","journal-title":"Prog Biochem Pharmacol"},{"key":"10.1038\/ki.1989.189_bb0145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0272-6386(86)80164-0","article-title":"Treatment of hyperlipidemia of the nephrotic syndrome: A controlled trial","volume":"6","author":"Valeri","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.1989.189_bb0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000184524","article-title":"Effect of probucol on hyperlipidemia in patients with nephrotic syndrome","volume":"47","author":"Iida","year":"1987","journal-title":"Nephron"},{"key":"10.1038\/ki.1989.189_bb0155","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1073\/pnas.84.16.5928","article-title":"Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, in animal model for familial hypercholesterolemia","volume":"84","author":"Kita","year":"1987","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1038\/ki.1989.189_bb0160","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ki.1988.125","article-title":"Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism","volume":"33","author":"Vega","year":"1988","journal-title":"Kidney Int"},{"key":"10.1038\/ki.1989.189_bb0165","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(88)90870-7","article-title":"Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome","volume":"2","author":"Rabelink","year":"1988","journal-title":"Lancet"},{"key":"10.1038\/ki.1989.189_bb0170","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/j.1552-4604.1987.tb05603.x","article-title":"The effect of renal function on the pharmokinetics of gemfibrozil","volume":"27","author":"Evans","year":"1987","journal-title":"J Clin Pharmacol"},{"key":"10.1038\/ki.1989.189_bb0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0002-9343(87)90692-9","article-title":"Hypertriglyceridemia: A controindication to the use of bile acid binding resins","volume":"83","author":"Crouse","year":"1987","journal-title":"Am J Med"},{"key":"10.1038\/ki.1989.189_bb0180","first-page":"99","article-title":"Lovastatin for hypercholesterolemia","volume":"29","year":"1987","journal-title":"Medical Letter"},{"key":"10.1038\/ki.1989.189_bb0185","first-page":"48","article-title":"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter)","volume":"318","author":"Tobert","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.1989.189_bb0190","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","article-title":"Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease","volume":"2","author":"Moorhead","year":"1982","journal-title":"Lancet"},{"key":"10.1038\/ki.1989.189_bb0195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/01.RES.62.2.367","article-title":"Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5\/6 nephrectomy model of chronic renal failure","volume":"62","author":"Kasiske","year":"1988","journal-title":"Circ Res"},{"key":"10.1038\/ki.1989.189_bb0200","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/ki.1987.259","article-title":"Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation","volume":"32","author":"Diamond","year":"1987","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815346305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815346305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T19:53:53Z","timestamp":1635537233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815346305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989,8]]}},"alternative-id":["S0085253815346305"],"URL":"https:\/\/doi.org\/10.1038\/ki.1989.189","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[1989,8]]}}}